Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 86, Issue 2, Pages 93-110
Publisher
Wiley
Online
2010-11-29
DOI
10.1111/j.1600-0609.2010.01558.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting CDC37: An alternative, kinase-directed strategy for disruption of oncogenic chaperoning
- (2011) Jennifer R. Smith et al. CELL CYCLE
- Shape Effect of Carbon Nanovectors on Angiogenesis
- (2010) Padmaparna Chaudhuri et al. ACS Nano
- Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo
- (2010) Phan LCHB Tran et al. BMC CANCER
- Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
- (2010) Warren Fiskus et al. CANCER BIOLOGY & THERAPY
- Hyperthermia-associated carboplatin resistance: Differential role of p53, HSF1 and Hsp70 in hepatoma cells
- (2010) Aanchal Sharma et al. CANCER SCIENCE
- Untangling the unfolded protein response
- (2010) Emma L. Davenport et al. CELL CYCLE
- Heat shock proteins as targets in oncology
- (2010) Alejandra Giménez Ortiz et al. Clinical & Translational Oncology
- New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells
- (2010) T. Nakashima et al. CLINICAL CANCER RESEARCH
- Novel therapeutic targets for multiple myeloma
- (2010) Anuj Mahindra et al. Future Oncology
- Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
- (2010) Joleen Hubbard et al. INVESTIGATIONAL NEW DRUGS
- Dual Role of Heat Shock Proteins as Regulators of Apoptosis and Innate Immunity
- (2010) Anne-Laure Joly et al. Journal of Innate Immunity
- Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
- (2010) J E Lancet et al. LEUKEMIA
- Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells
- (2010) Chun Hei Antonio Cheung et al. Molecular Cancer
- Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
- (2010) Diana Cirstea et al. MOLECULAR CANCER THERAPEUTICS
- Hsp90: A Drug Target?
- (2010) Jeffrey M. Holzbeierlein et al. Current Oncology Reports
- Modulation of Hsf1 activity by novobiocin and geldanamycin
- (2009) Renaud Conde et al. Biochemistry and Cell Biology
- Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
- (2009) J. Qian et al. BLOOD
- Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma
- (2009) Sagar Lonial et al. BRITISH JOURNAL OF HAEMATOLOGY
- Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800
- (2009) Thorsten Stühmer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Future Novel Single Agent and Combination Therapies
- (2009) Diana Cirstea et al. CANCER JOURNAL
- Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance
- (2009) C. Wong et al. CANCER RESEARCH
- Transcription Inhibition of Heat Shock Proteins: A Strategy for Combination of 17-Allylamino-17-Demethoxygeldanamycin and Actinomycin D
- (2009) F. Cervantes-Gomez et al. CANCER RESEARCH
- 17 AAG for HSP90 Inhibition in Cancer – From Bench to Bedside
- (2009) Saad Usmani et al. CURRENT MOLECULAR MEDICINE
- Update on Hsp90 Inhibitors in Clinical Trial
- (2009) Y. Kim et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
- (2009) Martin Kaiser et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- To fold or not to fold: modulation and consequences of Hsp90 inhibition
- (2009) Laura B Peterson et al. Future Medicinal Chemistry
- Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma
- (2009) Marco Breinig et al. HEPATOLOGY
- Activation of natural killer cells by heat shock protein 70
- (2009) Gabriele Multhoff INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8+ CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70
- (2009) Yufeng Xie et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation
- (2009) C. Fionda et al. JOURNAL OF IMMUNOLOGY
- Proteomic and Functional Analyses Reveal a Dual Molecular Mechanism Underlying Arsenic-Induced Apoptosis in Human Multiple Myeloma Cells
- (2009) Feng Ge et al. JOURNAL OF PROTEOME RESEARCH
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
- (2009) E Kastritis et al. LEUKEMIA
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
- (2009) Leandro C Cerchietti et al. NATURE MEDICINE
- Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression
- (2009) M. Tariq et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib
- (2009) Constantine S. Mitsiades et al. SEMINARS IN HEMATOLOGY
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
- (2008) Y. Okawa et al. BLOOD
- p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
- (2008) Kenji Ishitsuka et al. BRITISH JOURNAL OF HAEMATOLOGY
- HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma
- (2008) Ramadevi Nimmanapalli et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Pivotal Role for Heat Shock Protein 90 in Ewing Sarcoma Resistance to Anti-Insulin-like Growth Factor 1 Receptor Treatment: In vitro and In vivo Study
- (2008) A. S. Martins et al. CANCER RESEARCH
- Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
- (2008) Pascale Flandrin et al. CELL STRESS & CHAPERONES
- New insights into the mechanism of heat shock response activation
- (2008) I. Shamovsky et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers
- (2008) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment
- (2008) A. Huston et al. CLINICAL CANCER RESEARCH
- A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors
- (2008) A. N. Tse et al. CLINICAL CANCER RESEARCH
- A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies
- (2008) S. S. Ramalingam et al. CLINICAL CANCER RESEARCH
- Heat Shock Protein 90 as a Drug Target: Some Like It Hot
- (2008) U. Banerji CLINICAL CANCER RESEARCH
- Targeting Hsp90: small-molecule inhibitors and their clinical development
- (2008) Tony Taldone et al. CURRENT OPINION IN PHARMACOLOGY
- Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against Several Cancer Cell Lines
- (2008) Joseph A. Burlison et al. JOURNAL OF ORGANIC CHEMISTRY
- A Cremophor-Free Formulation for Tanespimycin (17-AAG) Using PEO-b-PDLLA Micelles: Characterization and Pharmacokinetics in Rats
- (2008) May P. Xiong et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
- (2008) M A Shammas et al. LEUKEMIA
- Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
- (2008) T Stühmer et al. LEUKEMIA
- Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors
- (2008) J R Smith et al. ONCOGENE
- Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?
- (2008) Paolo Decuzzi et al. PHARMACEUTICAL RESEARCH
- HSP90/70 chaperones are required for rapid nucleosome removal upon induction of the GAL genes of yeast
- (2008) M. Floer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The effect of particle design on cellular internalization pathways
- (2008) S. E. A. Gratton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now